EUVIMEDOpdag EUVIMED
Crossref

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors

Mayuri A Patil iD, Sachin S Bhusari, Pravin S Wakte

Chemical Biology & Drug Design · 2026-06 · 107 (6)

DOI: 10.1111/cbdd.70345 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-06-23. Written by Mayuri A Patil and 2 co-authors. Institution: Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, Maharashtra, India. Major MEDLINE topics: ErbB Receptors, Pyrazoles, Thiazoles, Drug Design. 42 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A novel series of thiazolyl–pyrazoline derivatives (MAP‐1 to MAP‐20) was designed and synthesized as potential epidermal growth factor receptor (EGFR) inhibitors. The structures of all compounds were confirmed by 1 H NMR, 13 C NMR, and HRMS analyses. The synthesized derivatives were evaluated for in vitro anticancer activity using the MTT assay against MCF‐7 (breast), A549 (lung), HeLa (cervical), and non‐tumorigenic MCF‐10A cell lines. Among the tested compounds, MAP‐13, MAP‐15, and MAP‐19 exhibited potent cytotoxic activity against MCF‐7 (IC 50 = 1.09 ± 0.8, 2.33 ± 0.84, and 2.11 ± 0.26 μM, respectively), A549 (IC 50 = 2.06 ± 0.16, 2.81 ± 0.16, and 2.76 ± 0.42 μM, respectively), and HeLa cells (IC 50 = 1.18 ± 0.9, 2.27 ± 0.18, and 2.15 ± 0.36 μM, respectively), with improved selectivity over normal MCF‐10A cells. Molecular docking studies against EGFR (PDB ID: 4I23) revealed strong binding affinities, with docking scores of −8.67, −9.31, and −9.00 kcal/mol for MAP‐13, MAP‐15, and MAP‐19, respectively. Key interactions within the ATP‐binding pocket suggested stable ligand–receptor complex formation. In silico ADMET profiling confirmed acceptable drug‐likeness and pharmacokinetic properties for the lead compounds. These findings indicate that thiazolyl–pyrazoline hybrids represent promising scaffolds for the development of selective EGFR‐targeted anticancer agents.

Subjects

MeSH terms (MEDLINE)

ErbB ReceptorsPyrazolesThiazolesDrug DesignAntineoplastic AgentsProtein Kinase InhibitorsHumansMolecular Docking SimulationCell Line, TumorBinding SitesMCF-7 CellsHeLa Cells

Author keywords

EGFR inhibitorsanticancerkinase inhibitionmolecular dockingthiazolyl–pyrazoline

Substances

ErbB ReceptorsPyrazolesThiazolesAntineoplastic AgentsProtein Kinase InhibitorsEGFR protein, human

Authors and institutions

  • Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, Maharashtra, India.

ORCID profiles: Mayuri A Patil

Cite

APA

Patil, M. A., Bhusari, S. S., & Wakte, P. S. (2026). Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70345

Vancouver

Patil MA, Bhusari SS, Wakte PS. Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70345

BibTeX
@article{Patil2026,
  author = {Patil, Mayuri A and Bhusari, Sachin S and Wakte, Pravin S},
  title = {Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl–Pyrazoline Derivatives as Potential EGFR Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {6},
  doi = {10.1111/cbdd.70345}
}
Start for free →